Italian-based biotech firm Stevanato Group and Bexson Biomedical Inc. announced a collaboration to treat a wide range of mental health issues with a subcutaneous drug-delivery device, including treatment-resistant depression and PTSD.
Since 2020, Stevanato and Bexson have been working to optimize the modularity of the SG EZ-be Pod, a small, wearable infusion device for the treatment of chronic and acute pain disorders. Their latest collaboration will grant Bexson access to the use of a customized version of the SG EZ-be Pod to develop new therapeutics that can treat a wide range of mental
Collaboration announced for device treating mental health issues
Italian-based biotech firm Stevanato Group and Bexson Biomedical Inc. announced a collaboration to treat a wide range of mental health issues with a subcutaneous drug-delivery device, including treatment-resistant depression and PTSD.
Since 2020, Stevanato and Bexson have been working to optimize the modularity of the SG EZ-be Pod, a small, wearable infusion device for the treatment of chronic and acute pain disorders. Their latest collaboration will grant Bexson access to the use of a customized version of the SG EZ-be Pod to develop new therapeutics that can treat a wide range of mental